

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/19603

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/00, 15/11, 15/09; A61K 48/ 00  
US CL : 536/23.1; 435/320.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 536/23.1; 435/320.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YAROSH et al. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine. 1996. vol. 14, no. 13, pages 1257-1264, see entire document	1-22
Y	KANELLOS et al. Naked DNA when co-administered intranasally with heat-labile enterotoxin of Escherichia coli primes effectively for systemic B-an T-cell responses to the encoded antigen. Immunology Letters. 2000. Vol. 74, pages 215-220, see entire document	1-22
Y	LEITNER et al. Nucleic Acid for the treatment of cancer:Genetic Vaccines and DNA Adjuvants. Current Pharmaceutical Design. 2001, vol. 7 pages 1641-1667, see entire document	1-22
Y	VELIN et al. Delivery Systems and Adjuvants for Vaccination against HIV. Pathobiology. 1998. Vol. 66, no. 3/4, pages 170-175, see entire document	1-22
A	GILBERT et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002. vol. 20, pages 1039-1045, see entire document	1-22

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 July 2005 (25.07.2005)

Date of mailing of the international search report

13 OCT 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Ram Shukla

Telephone No. (571) 272-0735

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US04/19603

Continuation of B. FIELDS SEARCHED Item 3:  
EAST: USPAT, USPGPUB, DERWENT, EPO  
STN:FILE Medline  
Search terms:adenovirus, vaccine, nucleic acid encoded adjuvant, CpG, oral, prime boost